Rare Primary Diffuse Large B-Cell Lymphoma Confined to Bone Marrow: Features and Prognosis
Our findings highlight the aggressive nature of PBM-DLBCL and underscore the importance of early recognition, risk stratification, and optimized treatment selection for this rare disease entity.
Authors
- Rong Fang
- Lu Lu (ORCID: https://orcid.org/0000-0002-6174-3209)
- Weiwei Chen (ORCID: https://orcid.org/0000-0003-2289-3578)
- Huiyu Li (ORCID: https://orcid.org/0000-0002-1977-3981)
- Xiaoyuan Chu (ORCID: https://orcid.org/0000-0002-7917-7874)
- Xiaodie Zhou
- Shuping Zhou (ORCID: https://orcid.org/0000-0003-1220-3019)
- Qian Sun (ORCID: https://orcid.org/0000-0003-3659-3242)
- Chunyan Zhu (ORCID: https://orcid.org/0000-0002-3434-2581)
- Yuchen Yang (ORCID: https://orcid.org/0000-0002-7124-5924)
Institutions
- Anhui University of Science and Technology (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.063484
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47